Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7535 in Healthy Subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HRS-7535 (Primary)
Indications Unspecified
Focus Adverse reactions
Sponsors Shandong Suncadia Medicine

Most Recent Events

06 Oct 2023 Results assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of single (n=24) and multiple (n=24) ascending doses (SAD and MAD) of HRS-7535 in healthy subjects, presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
26 Jun 2023 Status changed from not yet recruiting to recruiting according to results presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
26 Jun 2023 Results (n=48) presented at the 83rd Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com